PL363679A1 - Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów - Google Patents

Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów

Info

Publication number
PL363679A1
PL363679A1 PL02363679A PL36367902A PL363679A1 PL 363679 A1 PL363679 A1 PL 363679A1 PL 02363679 A PL02363679 A PL 02363679A PL 36367902 A PL36367902 A PL 36367902A PL 363679 A1 PL363679 A1 PL 363679A1
Authority
PL
Poland
Prior art keywords
power
phenyl
novel use
substituted imidazotriazinones
perception
Prior art date
Application number
PL02363679A
Other languages
English (en)
Inventor
Ulrich Niewohner
Erwin Bischoff
Helmut Haning
Afssaneh Rahbar
Tiemo-Joerg Bandel
Wolfgang Barth
Der Staay Franz-Josef Van
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10126198A external-priority patent/DE10126198A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PL363679A1 publication Critical patent/PL363679A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL02363679A 2001-05-09 2002-05-07 Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów PL363679A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10122576 2001-05-09
DE10126198A DE10126198A1 (de) 2001-05-09 2001-05-30 Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinonen
PCT/EP2002/005002 WO2002089808A1 (de) 2001-05-09 2002-05-07 Neue verwendung von 2-phenyl-substituierten imidazotriazinonen

Publications (1)

Publication Number Publication Date
PL363679A1 true PL363679A1 (pl) 2004-11-29

Family

ID=26009261

Family Applications (1)

Application Number Title Priority Date Filing Date
PL02363679A PL363679A1 (pl) 2001-05-09 2002-05-07 Nowe zastosowanie 2-fenylo-podstawionych imidazotriazynonów

Country Status (15)

Country Link
US (1) US20040152700A1 (pl)
EP (1) EP1392314B1 (pl)
JP (1) JP4540295B2 (pl)
CN (1) CN1633298A (pl)
AT (1) ATE348618T1 (pl)
AU (1) AU2002314044B2 (pl)
BR (1) BR0209541A (pl)
CA (1) CA2449163C (pl)
DE (1) DE50209015D1 (pl)
DK (1) DK1392314T3 (pl)
ES (1) ES2278927T3 (pl)
IL (1) IL158738A0 (pl)
MX (1) MXPA03010119A (pl)
PL (1) PL363679A1 (pl)
WO (1) WO2002089808A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001338T2 (tr) * 1997-11-12 2000-08-21 Bayer Aktiengesellschaft 2-Fenil-ikameli imidazotriazinonlar
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7666872B2 (en) 2004-03-05 2010-02-23 Nycomed Gmbh Use for PDE5 inhibitors
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
DE102005001989A1 (de) * 2005-01-15 2006-07-20 Bayer Healthcare Ag Intravenöse Formulierungen von PDE-Inhibitoren
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
DE102005009240A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
CA2623657A1 (en) * 2005-09-29 2007-04-12 Bayer Healthcare Ag Pde inhibitors and combinations thereof for the treatment of urological disorders
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
JP2010527928A (ja) 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用
EP2167057A1 (en) * 2007-06-13 2010-03-31 Bayer HealthCare AG Pde inhibitors for the treatment of hearing impairment
CN101965348B (zh) * 2007-09-06 2013-11-13 上海特化医药科技有限公司 伐地那非的制备方法及其中间体
ES2903151T3 (es) * 2012-12-04 2022-03-31 Aribio Inc Composición que comprende inhibidor de fosfodiesterasa tipo 5 para inhibir la apoptosis de células nerviosas
EP3887376A1 (en) 2018-11-28 2021-10-06 Topadur Pharma AG Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof
CN113493459B (zh) * 2020-04-07 2022-12-13 广州白云山医药集团股份有限公司白云山制药总厂 Pde5抑制剂化合物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2705715A (en) * 1952-10-29 1955-04-05 American Cyanamid Co Purine compounds and methods of preparing the same
CH367510A (de) * 1957-11-27 1963-02-28 Ciba Geigy Verfahren zur Herstellung neuer Sulfonamide
US3169129A (en) * 1963-05-10 1965-02-09 American Cyanamid Co 2-ortho-hydroxy-phenyl-4-(3h)-quinazolinones
US3333840A (en) * 1964-11-30 1967-08-01 Harbison Walker Refractories Method of lining a metallurgical furnace and the product thereof
USRE26565E (en) * 1966-03-02 1969-04-29 Table iii
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE791025A (fr) * 1971-11-19 1973-05-07 Allen & Hanburys Ltd Composes heterocycliques
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
US4052390A (en) * 1973-06-12 1977-10-04 May & Baker Limited Azapurinones
US4060615A (en) * 1976-02-18 1977-11-29 Mead Johnson & Company 2-Piperazinyl-6,7-dimethoxyquinazolines
GB1561345A (en) * 1976-10-22 1980-02-20 May & Baker Ltd 8 - azapuring - 6 - ones
US4159330A (en) * 1976-11-02 1979-06-26 Carlo Erba S.P.A. 2-Disubstituted phenyl-3,4-dihydro-4-oxo-quinazoline derivatives and process for their preparation
DK109578A (da) * 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
EP0054132B1 (de) * 1980-12-12 1984-10-10 Dr. Karl Thomae GmbH Neue Pyrimidinone, ihre Herstellung und Arzneimittel mit einem Gehalt an diesen Stoffen
US4431440A (en) * 1981-02-20 1984-02-14 American Cyanamid Company Method to alter or control the development and/or the life cycle of various plant species
JPS61237112A (ja) * 1985-04-12 1986-10-22 Matsushita Electric Works Ltd 電気機器の電力制御回路
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5254571A (en) * 1988-04-21 1993-10-19 Smith Kline & French Laboratories Ltd. Chemical compounds
DE68908786T2 (de) * 1988-06-16 1994-03-17 Smith Kline French Lab Condensierte Pyrimidinderivate, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
US5075310A (en) * 1988-07-01 1991-12-24 Smith Kline & French Laboratories, Ltd. Pyrimidone derivatives as bronchodilators
US4923874A (en) * 1988-07-21 1990-05-08 G. D. Searle & Co. Use of 8-azapurin-6-one derivatives for control of hypertension
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
US5574020A (en) * 1989-09-28 1996-11-12 Eli Lilly And Company Tilmicosin formulation
AU639988B2 (en) * 1990-04-11 1993-08-12 Pharmacia & Upjohn Company Taste masking of ibuprofen by fluid bed coating
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9114760D0 (en) * 1991-07-09 1991-08-28 Pfizer Ltd Therapeutic agents
US5316906A (en) * 1991-08-23 1994-05-31 Molecular Probes, Inc. Enzymatic analysis using substrates that yield fluorescent precipitates
GB9126260D0 (en) * 1991-12-11 1992-02-12 Pfizer Ltd Therapeutic agents
US5294612A (en) * 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9218322D0 (en) * 1992-08-28 1992-10-14 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
TR200001338T2 (tr) * 1997-11-12 2000-08-21 Bayer Aktiengesellschaft 2-Fenil-ikameli imidazotriazinonlar
DE19812462A1 (de) * 1998-03-23 1999-09-30 Bayer Ag 2-[2-Ethoxy-5(4-ethyl-piperazin-1-sulfonyl) -phenyl]-5-methyl-7-prophyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on Dihydrochlorid
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
GT199900061A (es) * 1998-05-15 2000-10-14 Pfizer Formulaciones farmaceuticas.
DE19827640A1 (de) * 1998-06-20 1999-12-23 Bayer Ag 7-Alkyl- und Cycloalkyl-substituierte Imidazotriazinone
EP1046150A1 (en) * 1998-10-27 2000-10-25 Koninklijke Philips Electronics N.V. Driving a matrix display panel
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
GB9923968D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Therapeutic agents
US6503908B1 (en) * 1999-10-11 2003-01-07 Pfizer Inc Pharmaceutically active compounds
WO2001047928A2 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Imidazo 1,3,5 triazinone und ihre verwendung
CA2406947A1 (en) * 2000-04-19 2001-10-25 Johns Hopkins University Methods for prevention and treatment of gastrointestinal disorders
WO2002009713A2 (de) * 2000-08-01 2002-02-07 Bayer Aktiengesellschaft Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung
ATE266407T1 (de) * 2000-10-30 2004-05-15 Lupin Ltd Schnell zerfallende cefuroxim axetil enthaltende arzneizusammensetzung mit verzögerter wirkstoffabgabe
EP1366760B1 (en) * 2001-02-15 2010-06-30 Mitsubishi Tanabe Pharma Corporation Tablets quickly disintegrated in oral cavity
DE10118306A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
DE10325813B4 (de) * 2003-06-06 2007-12-20 Universitätsklinikum Freiburg Prophylaxe und/oder Therapie bei der portalen Hypertonie
DE102004023069A1 (de) * 2004-05-11 2005-12-08 Bayer Healthcare Ag Neue Darreichungsformen des PDE 5-Inhibitors Vardenafil

Also Published As

Publication number Publication date
ATE348618T1 (de) 2007-01-15
CA2449163A1 (en) 2002-11-14
ES2278927T3 (es) 2007-08-16
EP1392314B1 (de) 2006-12-20
CA2449163C (en) 2010-07-13
DE50209015D1 (de) 2007-02-01
WO2002089808A1 (de) 2002-11-14
DK1392314T3 (da) 2007-03-12
MXPA03010119A (es) 2005-03-07
IL158738A0 (en) 2004-05-12
AU2002314044B2 (en) 2006-09-21
JP4540295B2 (ja) 2010-09-08
US20040152700A1 (en) 2004-08-05
BR0209541A (pt) 2004-04-20
JP2004528363A (ja) 2004-09-16
CN1633298A (zh) 2005-06-29
EP1392314A1 (de) 2004-03-03

Similar Documents

Publication Publication Date Title
WO2003055878A8 (de) 2-heteroarylcarbonsäureamide
IL158738A0 (en) Novel use of 2-phenyl-substituted imidazotriazinones
BG108443A (en) Substituted oxazoliidinones for combinational therapy
ATE427114T1 (de) Verwendung von hepcidin zur herstellung eines arzneimittels zur behandlung von eisenhomíostase stírungen
MXPA05011707A (es) Dihidroquinazolinas sustituidas con propiedades antivirales.
GB0111186D0 (en) Novel compounds
DE50305587D1 (en) 2-heteroarylcarbonsäureamide
IL163026A (en) Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders
WO2003078430A8 (de) Essig- und propionsäureamide
UA83821C2 (ru) Производные бензолсульфонамидов, способ их получения и их применение для лечения воспалительных заболеваний и утоления боли
MXPA05001885A (es) El uso de una combinacion de ciclesonida y antihistaminas para el tratamiento de la rinitis alergica.
MY139368A (en) Novel cyclohexyl sulphones
MXPA04000446A (es) 4-aminociclohexanoles sustituidos.
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
MXPA06000507A (es) Pirazolinas como antagonistas de par-1 para el tratamiento de enfermedades cardiovasculares.
AU2003245989A8 (en) Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
MXPA05010800A (es) Acidos hidroxamicos utiles en el tratamiento de trastornos hiperproliferativos.
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
MXPA03002047A (es) Fenilciclohexanocarboxamidas substituidas y su uso.
YU68403A (sh) Upotreba tiolutindioksida i njegovih derivata u proizvodnji leka i postupak za njihovo pripremanje
TW200508237A (en) 6-cyclylmethyl-and 6-alkylmethyl-substituted pyrazolopyrimidines
PL375354A1 (pl) Zastosowanie treosulfanu i jego pochodnych do leczenia stwardnienia rozsianego
PT1814879E (pt) Derivados de 4,7-dioxobenzotiazole-2-carboxamidas, sua preparação e suas aplicações terapêuticas
WO2003064394A8 (de) 5-ring heterozyklen zur verwendung als antiviral mittel
MXPA04000953A (es) Derivados sustituidos del acido 5,6,6a,11b-tetrahidro-7-oxa-aza-benzo[c]fluoren-6-carboxilico como antagonista de nmda.

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)